SCHEMBL3274182

SCHEMBL3274182

Cc1ccc2c(Br)c(C)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
HSD17B10 Q99714 3/20 0.59
LMNA P02545 2/20 0.59
HPGD P15428 2/20 0.59
KDM4E B2RXH2 1/20 0.59
GAA P10253 1/20 0.59
CYP1A2 P05177 7/20 0.52
CYP2A6 P11509 6/20 0.50
TDP1 Q9NUW8 3/20 0.43
NCK1 P16333 1/20 0.35
BACE1 P56817 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CA12 O43570 3/20 0.34
CA9 Q16790 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267082 0.84 CYP1A2 (0.54) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL30640484 0.84 CYP1A2 (0.54) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL27850307 0.83 CYP1A2 (0.50) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL8474786 0.83 NCEH1 (0.46) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL13210762 0.80 HSD17B1 (0.50) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL5511551 0.79 CYP1A2 (0.40) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL13296157 0.79 ESR1 (0.49) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL16153617 0.79 ALDH1A1 (0.55) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL13964535 0.79 ESR1 (0.58) ALDH1A1HSD17B10LMNAHPGDKDM4E
SCHEMBL607927 0.78 CYP1A2 (0.71) ALDH1A1HSD17B10LMNAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023214325-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS NOVARTIS AG (CH) 2023-11-09 WO disclosed
CN-107778212-A One kind 1,5 2 substitutes naphthalene derivatives and its application 北京鼎材科技有限公司 2018-03-09 CN disclosed
CN-107778213-A One kind 1,4 2 substitutes naphthalene derivatives and application 北京鼎材科技有限公司 2018-03-09 CN disclosed
US-20100327274-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-12-30 US disclosed
US-20100327274-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-12-30 US disclosed
EP-1914229-B1 NOVEL CERCOSPORAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-06-16 EP disclosed
WO-2009123344-A1 ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2009-10-08 WO disclosed
US-20090036492-A1 Novel Cercosporamide Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1914229-A1 NOVEL CERCOSPORAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036492-A1 Novel Cercosporamide Derivative GPR119, CBR3, SLC5A2 ALDH1A1 381/4885HSD17B10 708/4885LMNA 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.